antibody_history

Rituximab marked a milestone as the first cancer antibody. Biointron reviews its approval, clinical use, and role in shaping oncology therapeutics.

ADCs have evolved into powerful cancer drugs. Biointron reviews their history, design improvements, and future directions in targeted therapy.

VHH antibodies offer stability, small size, and strong binding. Biointron highlights their promise in diagnostics, therapeutics, and next-generation antibody design.

Muronomab (Orthoclone OKT3) made history as the first FDA-approved monoclonal antibody. Biointron reviews its impact on immunotherapy and antibody drug development.

scFvs combine compact design with strong binding. Biointron explores their history, therapeutic applications, and role in diagnostics and research innovation.

Discover highlights from Biointron’s Lunch & Learn with MassBio, featuring HTP antibody platforms, alpaca VHH discovery, bispecific antibodies, and ADC development.

VHH antibodies have reshaped biotech. Biointron reviews their discovery, unique advantages, and applications driving innovation in diagnostics and therapeutic development.

Biointron celebrates the International Day of Women and Girls in Science, honoring contributions that drive antibody discovery, biotech innovation, and global progress.